Evidence map›Paper›PMID 28082811›Full record

ArticleWorld journal of gastroenterology2016

Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.

Piers Gatenby, Santanu Bhattacharjee, Christine Wall, Christine Caygill, Anthony Watson

Abstract read
In one paragraph

Article in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Gastrointestinal Tract Disorders in Older Age.Canadian journal of gastroenterology & hepatology · 2019
    Review
  3. Article
  4. Endoscopic therapy for confirmed low-grade dysplasia in Barrett's esophagus.Translational gastroenterology and hepatology · 2018
    Review
  5. Barrett's oesophagus: Current controversies.World journal of gastroenterology · 2017
    Review
  6. Artificial intelligence in endoscopy: Overview, applications, and future directions.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Piers GatenbyPiers Gatenby, Santanu Bhattacharjee, Christine Wall, Christine Caygill, Anthony Watson, United Kingdom Barrett's Oesophagus Registry, UCL, NW32QG London, United Kingdom.
Santanu BhattacharjeePiers Gatenby, Santanu Bhattacharjee, Christine Wall, Christine Caygill, Anthony Watson, United Kingdom Barrett's Oesophagus Registry, UCL, NW32QG London, United Kingdom.
Christine WallPiers Gatenby, Santanu Bhattacharjee, Christine Wall, Christine Caygill, Anthony Watson, United Kingdom Barrett's Oesophagus Registry, UCL, NW32QG London, United Kingdom.
Christine CaygillPiers Gatenby, Santanu Bhattacharjee, Christine Wall, Christine Caygill, Anthony Watson, United Kingdom Barrett's Oesophagus Registry, UCL, NW32QG London, United Kingdom.
Anthony WatsonPiers Gatenby, Santanu Bhattacharjee, Christine Wall, Christine Caygill, Anthony Watson, United Kingdom Barrett's Oesophagus Registry, UCL, NW32QG London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo clarify risk based upon segment length, diagnostic histological findings, patient age and year of surveillance, duration of surveillance and gender.

methodsPatients registered with the United Kingdom Barrett's Oesophagus Registry from 9 United Kingdom centers were included. The outcome measures were (1) development of all grades of dysplasia; (2) development of high-grade of dysplasia or adenocarcinoma; and (3) development of adenocarcinoma. Prevalent cases and subjects with < 1 year of follow-up were excluded. The covariates examined were segment length, previous biopsy findings, age at surveillance, duration of surveillance, year of surveillance and gender.

resultsOne thousand and one hundred thirty six patients were included (total 6474 patient-years). Fifty-four patients developed adenocarcinoma (0.83% per annum), 70 developed high-grade dysplasia/adenocarcinoma (1.1% per annum) and 190 developed any grade of dysplasia (3.5% per annum). High grade dysplasia and adenocarcinoma increased with age and duration of surveillance. The risk of low-grade dysplasia development was not dependent on age at surveillance. Segment length and previous biopsy findings were also significant factors for development of dysplasia and adenocarcinoma.

conclusionThe risk of development of low-grade dysplasia is independent of age at surveillance, but high-grade dysplasia and adenocarcinoma were more commonly found at older age. Segment length and previous biopsy findings are also markers of risk. This study did not demonstrate stabilisation of the metaplastic segment with prolonged surveillance.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAge FactorsBarrett EsophagusBiopsyCell Transformation, NeoplasticCohort StudiesDisease ProgressionEsophageal NeoplasmsEsophagoscopyFemaleFollow-Up StudiesHumansIncidenceBarrett’s esophagusDysplasiaEpidemiologyEsophageal neoplasmsPublic healthSurveillance

Identifiers

PMID28082811
PMCPMC5192270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.